On January 8, 2024, the US Food and Drug Administration (FDA) issued a landmark announcement: vaporized hydrogen peroxide (VHP) is now considered an established method of sterilization for medical devices. By adding VHP to Established Category A, the FDA has recognized its long history of safety and effectiveness, placing it alongside moist heat, dry heat, ethylene oxide (EtO), and radiation.

This decision represents the regulatory formalization of a decade-long convergence between growing evidence of EtO’s carcinogenic risk and the maturation of validation frameworks like ISO 22441:2022. For medical device manufacturers, this is not just a classification change—it is a strategic shift in how products will be sterilized for the next decade.

VHP joining Established Category A is not a regulatory footnote. It is the FDA signalling the direction of travel for medical device sterilization for the next decade.

1. Regulatory Architecture: What Established Category A Actually Means

The FDA divides sterilization methods into two categories to determine the level of information required in premarket submissions (510(k)):

• Established Category A: Methods with a long history of safe use and recognized consensus standards. Submissions follow a predictable and streamlined review pathway.
• Category B (Novel): Methods that lack the same history, requiring extensive scientific rationale and additional validation data.

Before January 2024, VHP was a Category B method. Despite its widespread use in pharmaceuticals, manufacturers faced a higher regulatory burden. The elevation to Category A, following the recognition of ISO 22441:2022, creates a 510(k) submission pathway for VHP that is equivalent in predictability to EtO and radiation.

2. Why January 2024? The Convergence of Regulatory Pressure

The decision was driven by the need for a viable ethylene oxide alternative FDA-supported pathway. Ethylene oxide currently sterilizes approximately 50% of all sterile medical devices in the US, but its dependence on a Group 1 human carcinogen has created significant supply chain fragility.

The 2019 closure of major EtO facilities due to EPA emissions enforcement highlighted this risk. By elevating VHP, the FDA is actively encouraging the diversification of sterilization methods to ensure patient safety and supply chain resilience.

3. What the FDA Decision Does Not Mean

It is important to clear common misconceptions about this regulatory shift:

• It does not mean EtO is being eliminated: EtO remains irreplaceable for devices requiring deep penetration through complex internal geometries or long lumens.
• It does not mean VHP validation is trivial: A VHP process still requires full development and validation per ISO 22441:2022. The Category A status simply streamlines the submission process, not the technical requirements.
• The EPA reconsideration does not reverse this: While the EPA may reconsider specific emissions rules (NESHAP), the FDA’s recognition of VHP as a safe and effective Category A method remains unchanged.

4. Strategic Implications for Manufacturers

For medical device manufacturers, the January 2024 decision creates a clear opportunity to reduce EtO dependence. The DeloxHP platform, a solid-state VHP system, is designed to support this transition by providing a controlled and reproducible sterilization profile that aligns with modern regulatory expectations.

4.1 Portfolio Assessment: Which Devices Can Transition?

Manufacturers should evaluate their portfolios based on:

• Penetration requirements: Surface-sterilized devices and instruments are ideal candidates for VHP.
• Material compatibility: VHP is compatible with most polymers and metals, though it degrades cellulosic materials (paper/cotton).
• Packaging: Tyvek-based systems are broadly compatible with VHP sterilization.

5. EtO vs. VHP: Regulatory Comparison (Post-January 2024)

6. Conclusion

The FDA’s elevation of VHP to Established Category A is the most significant regulatory development in sterilization in a decade. It transforms VHP into a fully equivalent, FDA-supported, and ISO-standardized ethylene oxide alternative. The question for manufacturers is no longer whether VHP is regulatory-grade—it is which products can transition to this safer, more efficient pathway.

Frequently Asked Questions

What did the FDA decide about VHP sterilization in January 2024?

The FDA elevated vaporized hydrogen peroxide (VHP) to Established Category A, recognizing it as an established sterilization method for medical devices, equivalent to ethylene oxide and radiation.

Is VHP an FDA-approved ethylene oxide alternative?

Yes. As of January 2024, VHP follows the same streamlined 510(k) submission pathway as EtO, provided it is validated according to the ISO 22441:2022 standard.

What is ISO 22441:2022?

It is the international standard for VHP sterilization of medical devices. The FDA’s recognition of this standard was the technical basis for elevating VHP to Category A status.